Scholarlink

Background <p>Anti-epidermal growth factor receptor (EGFR) antibodies are widely used in the treatment of RAS wild-type metastatic colorectal cancer (mCRC) across various lines of therapy, including after disease progression. However, evidence from randomized controlled trials regarding the efficacy of cetuximab rechallenge in patients who initially responded to prior cetuximab but subsequently progressed after a cetuximab-free interval remains limited.</p> Methods <p>This single-center, prospective, exploratory randomized trial (ChiCTR1900026961) evaluated cetuximab plus irinotecan rechallenge versus regorafenib in patients with RAS wild-type, microsatellite-stable mCRC who had previously responded to then progressed off cetuximab. Progression-free survival (PFS) was the primary endpoint, with overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety as secondary endpoints. Univariate and multivariate Cox regression analyses were performed to identify potential prognostic factors, and an exploratory nomogram was developed for hypothesis generation.</p> Results <p>Among 68 randomized patients, cetuximab plus irinotecan rechallenge was associated with longer median PFS and OS than regorafenib. The DCR and ORR were numerically higher in the rechallenge group. Median PFS was 5.5 months versus 2.6 months, and median OS was 18.8 months versus 10.4 months. Adverse events in the cetuximab group were predominantly grade 1–2 and manageable with supportive care. Univariate and multivariate analyses identified age, ECOG status, and cetuximab-free interval as potential prognostic factors. An exploratory nomogram was constructed based on these factors.</p> Conclusions <p>These findings suggest that cetuximab plus irinotecan rechallenge may be associated with clinical benefit and acceptable toxicity in selected patients with RAS/BRAF wild-type mCRC. The exploratory nomogram requires further validation. These results support further investigation of rechallenge strategies and biomarker-guided approaches in advanced CRC.</p> Trial registration <p>This study was registered with the Chinese Clinical Trial Registry on October 27, 2019 (registration number: ChiCTR1900026961).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Hao Chen,
  • Tao Jiang,
  • Han Wang,
  • Jianwei zheng,
  • Bin Du,
  • Xiaojiao Weng,
  • Na Yao,
  • Yingjiao Zhu,
  • Qing Liu,
  • Fangyu Lin,
  • Xinli Wang,
  • Xiaoyan Lin

摘要

Background

Anti-epidermal growth factor receptor (EGFR) antibodies are widely used in the treatment of RAS wild-type metastatic colorectal cancer (mCRC) across various lines of therapy, including after disease progression. However, evidence from randomized controlled trials regarding the efficacy of cetuximab rechallenge in patients who initially responded to prior cetuximab but subsequently progressed after a cetuximab-free interval remains limited.

Methods

This single-center, prospective, exploratory randomized trial (ChiCTR1900026961) evaluated cetuximab plus irinotecan rechallenge versus regorafenib in patients with RAS wild-type, microsatellite-stable mCRC who had previously responded to then progressed off cetuximab. Progression-free survival (PFS) was the primary endpoint, with overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety as secondary endpoints. Univariate and multivariate Cox regression analyses were performed to identify potential prognostic factors, and an exploratory nomogram was developed for hypothesis generation.

Results

Among 68 randomized patients, cetuximab plus irinotecan rechallenge was associated with longer median PFS and OS than regorafenib. The DCR and ORR were numerically higher in the rechallenge group. Median PFS was 5.5 months versus 2.6 months, and median OS was 18.8 months versus 10.4 months. Adverse events in the cetuximab group were predominantly grade 1–2 and manageable with supportive care. Univariate and multivariate analyses identified age, ECOG status, and cetuximab-free interval as potential prognostic factors. An exploratory nomogram was constructed based on these factors.

Conclusions

These findings suggest that cetuximab plus irinotecan rechallenge may be associated with clinical benefit and acceptable toxicity in selected patients with RAS/BRAF wild-type mCRC. The exploratory nomogram requires further validation. These results support further investigation of rechallenge strategies and biomarker-guided approaches in advanced CRC.

Trial registration

This study was registered with the Chinese Clinical Trial Registry on October 27, 2019 (registration number: ChiCTR1900026961).